MedTech-related technology assessments and clinical guidelines from NICE in May 2022

31

May 2022

IPG is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

In May 2022, NICE published three new Interventional Procedures Guidance (IPG) and provided the following conclusions:

  • For people with unfavorable aneurysm morphology needing an EVAR as a primary procedure, or for people with an existing EVAR who need a secondary procedure, evidence on the safety of using endoanchoring systems is adequate, but evidence on efficacy is limited in quantity and quality. Therefore, it should only be used with special arrangements for clinical governance, consent, and audit or research;
  • For people with favorable aneurysm morphology needing an EVAR as a primary procedure, evidence on the safety of using endoanchoring systems is adequate. However, evidence on efficacy is inadequate in quantity and quality. Therefore, for these people, this procedure should only be used in the context of research.

Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.

In May 2022, NICE issued one new MTGs on Sleepio to treat insomnia and insomnia symptoms, which provided the following recommendations:

  • Sleepio is recommended as a cost-saving option for treating insomnia and insomnia symptoms in primary care for people who would otherwise be offered sleep hygiene or sleeping pills;
  • For people who may be at higher risk of other sleep disorder conditions, such as in pregnancy or in people with comorbidities, a medical assessment should be done before referral to Sleepio;
  • More research or data collection is recommended on Sleepio for people who are eligible for face-to-face cognitive behavioral therapy for insomnia (CBT‑I) in primary care. This is because there is limited clinical evidence to show how effective Sleepio is compared with face-to-face CBT‑I.

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations. The six new MIBs published in May 2022 are:

See the full details here

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

05

Dec 2022

On November 17, 2022, the Ministry of Health and Prevention published the Order in the Official Journal of the French Republic on the extension of the national newborn screening by laboratory diagnostics to seven more diseases (inborn errors of metabolism).

Read more

01

Dec 2022

In November 2022, NHS Accelerated Access Collaborative decided not to add new technologies to MedTech Funding Mandate (MTFM) in 2023/24. Instead, Integrated Care Systems (ICSs) are asked to prioritize the appropriate adoption of currently supported technologies where this has not yet occurred. The MTFM supports eleven NICE-approved and cost-saving devices, diagnostics, and digital products, making them mandatory for implementation and funding.

Read more

29

Nov 2022

On November 18, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) announced that sixteen applications for Innovation Funding of the new forms of care were accepted. These applications relate to the funding announcement of March 17, 2021. Most projects relate to interdisciplinary or cross-sectoral care and pathways.

Read more

24

Nov 2022

In November 2022, NHS Digital published a final summary of core changes from OPCS-4.9 to OPCS-4.10 to be introduced from April 01, 2023. OPCS-4 is a statistical classification for clinical coding of interventions and procedures undertaken within the NHS. It is updated every three years. A total of 236 new four-character codes will be implemented in OPCS-4.10. Key changes concern cardiovascular, gastrointestinal, endoscopy, ENT, nephrology and urology, neurology and neurosurgery, obstetrics and gynecology, orthopedic, and breast surgery fields.

Read more

23

Nov 2022

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 21738 of November 4, 2022, Tuscany Regional Healthcare has published assessments of three medical devices in the orthopedics, surgical procedures, and peripheral vascular areas.

Read more